<h2>Congress Members Challenge Proposed Cannabis Rescheduling</h2>
<p>In a significant policy development, several U.S. Congress members have voiced strong opposition to the proposed rescheduling of cannabis. A letter, dated August 28, 2025, and addressed to Attorney General Pam Bondi, urged the rejection of recommendations to classify cannabis as a Schedule III drug. This decision comes in the wake of a suggestion by the Food and Drug Administration in 2024, pushing for a reclassification under the Controlled Substances Act (CSA). This move, the letter argues, could signal a lenient stance towards cannabis, potentially facilitating tax benefits for large cannabis corporations and even foreign drug cartels.</p>
<p>President Donald Trump, also a recipient of the correspondence, has previously commented on the Cannabis rescheduling matter. Indicating an imminent decision, the Trump Administration's stance promises to reshape cannabis policy and influence subsequent legislative approaches.</p>
<h3>Core Arguments Against Rescheduling</h3>
<p>The arguments presented in the Congress members' letter rest on three pivotal points. Firstly, the letter articulates concerns about cannabis’s addictive potential and its alleged lack of medical value. It cites research linking cannabis to various mental health issues, including psychosis and anxiety, while emphasizing risks such as strokes and heart attacks. Further, it warns against potential tax code loopholes that could benefit illegal enterprises, currently restricted by tax code 280E.</p>
<p>Additionally, the letter raises alarms about the implications for youth, suggesting that rescheduling might downplay cannabis's risks, inadvertently promoting early use. Finally, it equates medical and recreational cannabis due to current dispensary practices and highlights potential health risks associated with smoking cannabis, pointing to research on its adverse effects on veterans with PTSD.</p>
<h3>Insights from Congressional Leaders</h3>
<p>Key figures, such as Congressman Pete Sessions and Paul Gosar, have been vocal in their positions. Sessions, a long-time opponent of rescheduling, reiterated the purported dangers of cannabis, expressing concern over its growing potency and addiction potential. He emphasized that reclassification could lead to a public health crisis by normalizing cannabis use among children.</p>
<p>Congressman Gosar, who contributed personal op-eds on the matter, echoed similar sentiments, cautioning against the public perception that reduced scheduling might foster, despite increasing cannabis potency. Both leaders emphasize cannabis's escalating risks, reinforcing their commitment to maintaining its current legal status as a protective measure.</p>
<h3>Legislative Developments and Future Implications</h3>
<p>Following the letter's release, significant legislative movements continue to unfold. The MORE Act, reintroduced in Congress by prominent figures such as Congressman Jerrold Nadler and members of the Cannabis Caucus, seeks to address broader reform by rescheduling cannabis and expunging past convictions. The bill illustrates the ongoing tension and debate surrounding federal cannabis policy and its social and economic ramifications.</p>
<p>As these discussions advance, the decisions made will heavily influence the trajectory of cannabis legislation, potentially reshaping industry dynamics and societal perceptions. Canna Daily News remains committed to providing comprehensive coverage and analysis of these pivotal developments, supporting informed dialogue and action within the cannabis community.</p>
<p>#CannabisRescheduling #CannabisPolicy #MOREAct #CannabisIndustryNews #ProtectOurYouth</p>